Balance Sheet (Annual)

LAD / Lithia Motors, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Accounts Receivable Net Current - 133,149 170,519 295,379 308,462 417,714 521,938
  Current Assets
  Cash And Cash Equivalents At Carrying Value 20,851 42,839 23,686 29,898 45,008 50,282 57,253
  Receivables Net Current 99,407 133,149 170,519 - - - -
  Inventory Net 506,484 723,326 859,019 1,249,659 1,470,987 1,772,587 2,132,744
  Deferred Tax Assets Net Current 4,730 3,832 1,548 - - - -
  Other Assets Current 16,719 17,484 15,251 32,010 54,408 46,611 70,847
  Assets Held For Sale Current - 12,579 11,526 - - - -
  Assets Of Disposal Group Including Discontinued Operation Current - - - 8,563 - - -
  Assets Current 648,191 933,209 1,081,549 1,615,509 1,878,865 2,287,194 2,782,782
  Property Plant And Equipment Net 373,779 425,086 481,212 816,745 876,660 1,006,130 1,185,169
  Goodwill 18,958 32,047 49,511 199,375 213,220 259,399 256,320
  Indefinite Lived Franchise Rights 59,095 62,429 71,199 150,892 157,699 184,268 186,977
  Deferred Tax Assets Net Noncurrent 29,270 17,123 10,256 - - - -
  Other Assets Noncurrent 16,840 22,808 31,394 98,411 100,855 107,159 271,818
  Assets 1,146,133 1,492,702 1,725,121 2,880,932 3,227,299 3,844,150 4,683,066
Liabilities And Stockholders Equity
  Liabilities Current
    Deferred Tax Liabilities Current - - - 2,603 - 59,075 -
    Liabilities Of Disposal Group Including Discontinued Operation Current - - - 4,892 - - -
  Current Liabilities
  Floor Plan Notes Payable 114,760 13,454 18,789 41,047 48,083 94,602 116,774
  Floor Plan Notes Payable Non Trade 229,180 568,130 695,066 1,137,632 1,265,872 1,506,895 1,802,252
  Deferred Tax Liabilities Noncurrent - - - 42,795 53,129 - -
  Long Term Debt And Capital Lease Obligations Current 8,221 8,182 7,083 31,912 38,891 20,965 18,876
  Accounts Payable Current 31,712 41,589 51,159 70,853 70,871 88,423 111,362
  Deferred Income Tax Liabilities Net - - - - - - 56,277
  Accrued Liabilities Current 72,711 81,602 94,143 153,661 167,108 211,109 251,717
  Liabilities Of Disposal Group Including Discontinued Operation - - - 4,892 - - -
  Liabilities Of Assets Held For Sale - 8,347 6,271 - - - -
  Liabilities Current 456,584 721,304 872,511 1,442,600 1,590,825 1,921,994 2,300,981
  Long Term Debt And Capital Lease Obligations - 286,876 245,471 609,066 606,463 769,916 1,028,476
  Deferred Revenue Noncurrent 25,146 33,589 44,005 54,403 66,734 81,929 103,111
  Other Liabilities Noncurrent 18,629 22,832 28,412 58,963 81,984 100,460 111,003
  Liabilities 779,012 1,064,601 1,190,399 2,207,827 2,399,135 2,933,374 3,599,848
  Stockholders Equity
    Preferred Stock Value - - - 0 0 0 0
  Common Stock Value - - - - - - -
  Additional Paid In Capital Common Stock 10,918 12,399 22,598 29,775 38,822 41,225 11,309
  Accumulated Other Comprehensive Income Loss Net Of Tax -4,508 -2,615 -1,538 -926 -277 - -
  Retained Earnings Accumulated Deficit 80,877 149,173 245,088 367,879 530,893 703,820 922,662
  Stockholders Equity 367,121 428,101 534,722 673,105 828,164 910,776 1,083,218
  Liabilities And Stockholders Equity 1,146,133 1,492,702 1,725,121 2,880,932 3,227,299 3,844,150 4,683,066

Peers - Automotive Dealers And Gasoline Service Stations (55)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 536797103